Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has been upgraded by Barclays, which now rates the stock as Equal Weight versus Underweight prior rating, according to a note issued on May 21. Analysts at B. Riley FBR, Inc., started covering the stock on February 08 with a Neutral rating. Brokerage firm Ladenburg Thalmann, looks cautious as they stick to prior recommendation of Buy, in a call on September 12. However, they did change the target price from $9 to $6.50.
ACHN stock dropped -0.99% in recent trade and currently has a stock-market value of $417.31M. The shares finished at $3.01, after trading as low as $2.935 earlier in the session. It hit an intraday high Thursday at $3.12. Trading activity significantly improved as the volume at ready counter increased to 2,111,613 shares versus 1,483,635 in average daily trading volume over the past 20 days. So far this year, the volume has averaged about 1,943,054 shares. The stock is now 133.33% above against its bear-market low of $1.29 on December 20, 2018. It has retreated -38.87% since it’s 52-week high of $4.18 reached in March. Now the market price is down -25.68% on the year and up 89.31% YTD.
Wall Street’s most bullish Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) analysts are predicting the share price to blow past $6 per share during the next 12 months. The current median share price forecast by them is $5.5, suggesting that the stock could increase 82.72% in that time frame. The average price target of $5.5 calls for a nearly 82.72% increase in the stock price.
Achillion Pharmaceuticals, Inc. (ACHN)’s 50 day simple moving average (SMA 50) price is $2.34 and its 200-day simple moving average (SMA 200) price is $2.78. The company’s stock currently has a total float of 138.41M shares. Its weekly volatility is hovering around 5.28% and felt 5.87% volatility in price over a month. On the upside, the share price will test short term resistance at around $3.11. On a downside, the stock is likely to find some support, which begins at $2.92. The failure to get near-term support could push it to $2.84.
Also, it is trading at rather expensive levels at just over 1.57x price/book and 0x price/sales. ACHN’s ROE is -24.5%, which is also considerably worse than the industry’s ROE of 9.84%. It’s also very liquid in the near term, with a current ratio of 23.3. The stock has a debt/capital of 0.
Shares of ACHN have gained 13.9% since the company’s most recent earnings report. Over the past 12 fiscal quarters, Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has topped consensus earnings estimates in 8 quarters (66%), missed earnings in 3 quarters (25%), whereas at 1 occasion EPS met analyst expectations. ACHN last reported earnings that exceeded expectations. The company raked in -$0.12 per share, -99.4% change on the same period last year. That was better than consensus for -$0.15. For this quarter, Wall Street analysts forecast revenue in a range of $0 to $0, which should be compared with $0 generated last year. EPS is seen in a range of -$0.14 to -$0.13, against the -$0.19 reported a year ago.